← Human Trials & Peer-Reviewed Studies
Comparative study between oxytocin and combination of tranexamic acid and ethamsylate in reducing intra-operative bleeding during emergency and elective cesarean section after 38 weeks of normal pregnancy.
Plain-language guide to PMID 37308871 (2023): double-blind randomized controlled trial of Oxytocin.
Key Facts
- PMID
- 37308871
- Journal
- BMC pregnancy and childbirth
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Bosilah AH et al. (15 authors)
- DOI
- 10.1186/s12884-023-05728-w
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Oxytocin, published as a randomized controlled trial.
The researchers aim to compare the combination of ethamsylate and tranexamic acid, oxytocin, and placebo in women undergoing CS.
The one-way ANCOVA test was used to compare the quantitative variables between the three groups while the Chi-square test was used to compare the qualitative variables.
Post hoc analysis then was performed to compare the difference between every two groups regarding the quantitative variables.
Why It Was Studied
The study was registered on Pan African Clinical Trials Registry with the following number: PACTR202009736186159 and was approved on 04/09/2020.
Who Took Part
PubMed tags the participants as women only.
The study included all pregnant women in labor without any complications who accepted to participate in the study between October and December 2020.
The participants were divided into three groups.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Oxytocin could be set against what happens without it.
The researchers conducted a double-blinded, randomized, placebo-controlled trial between October and December 2020 in four university hospitals in Egypt.
Their main outcome was the amount of blood loss during the operation.
The secondary outcomes were the need for blood transfusion, hemoglobin and hematocrit changes, hospital stay, operative complications, and the need for a hysterectomy.
What Was Measured
PubMed files the paper under topics including Blood Loss, Surgical, Cesarean Section, Ethamsylate, Oxytocin, Tranexamic Acid and Pregnancy Trimester, Third.
The authors tagged it with the keywords Elective cesarean section, Emergency cesarean section and Intra-operative and post-operative bleeding.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Oxytocin.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (BMC pregnancy and childbirth), a journal based in England.
More context: the Oxytocin compound page, all human trials.
Our Notes on the Compound
Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.